Sign up for the QMED & MD+DI Daily newsletter.
Diving into Medtech's M&A in 2021
Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers discusses the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report. Hunzinger also talks about some trends in medtech M&A and the rise of the Special Purpose Acquisition Corporation mergers. Plus, MD+DI’s Omar Ford gives insight on Illumina’s controversial acquisition of Grail.
Omar Ford
August 26, 2021
1 Min Read
onephoto-stock.adobe.com
This episode of Let’s Talk Medtech is a double-header. We speak with Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers about the state of medtech M&A and take a dive into the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report.
Then, Omar Ford, MD+DI’s Managing Editor, delves into the controversial Illumina/Grail merger.
About the Author(s)
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
